Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
Savara Inc Chief Financial Officer David L. Lowrance exercised several stock option grants on March 18, 2026, acquiring a total of 366,747 shares of Common Stock through option exercises at strike prices ranging from $1.11 to $4.45 per share. To cover exercise costs and tax obligations, 116,760 shares of Common Stock were withheld by the issuer in transactions coded as F, which are tax-withholding dispositions rather than open‑market sales. Following these transactions, Lowrance directly owned 536,032 shares of Savara common stock. The derivative transactions reflect routine option exercises tied to grants that vest in quarterly installments, as described in the footnotes.
Savara Inc. entered into a new headquarters lease with ML7 Yardley Partners, LP for approximately 10,795 square feet of office space at 19 W. College Avenue, Suite 200, Yardley, Pennsylvania. The lease term begins on July 1, 2026 and runs through December 1, 2031, with an option to extend for an additional five years.
Savara will pay monthly base rent of about $28,337 in the first year, with annual increases of roughly 2%. Aggregate base rent over the term is approximately $1,780,900, reflecting five months of rent abatement. The company will also pay its share of operating expenses, taxes, and utilities and has provided a $28,337 security deposit.
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, built around its sole product candidate, MOLBREEVI (molgramostim inhalation solution) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The drug is an inhaled form of GM-CSF delivered via PARI’s proprietary eFlow nebulizer.
The company’s Phase 3 IMPALA-2 trial in autoimmune PAP met its primary endpoint, showing statistically significant improvement in gas exchange (DLCO) and supporting clinical benefit on respiratory quality of life and exercise capacity, with generally well-tolerated safety. A pediatric trial (IMPACT) and an expanded access program are ongoing.
Savara resubmitted a biologics license application for MOLBREEVI in autoimmune PAP in December 2025, and in February 2026 the FDA filed the application and granted Priority Review. The candidate holds multiple regulatory incentives, including Orphan Drug, Fast Track, Breakthrough Therapy, Innovation Passport, and Promising Innovative Medicine designations, as well as European patents protecting the liquid formulation and the MOLBREEVI–eFlow drug-device combination into the 2040s.
The company outsources manufacturing to GEMA, Fujifilm, and Patheon and has exclusive device supply from PARI. Under a purchase and sale agreement with funds managed by RTW Investments, Savara may receive $75 million upon FDA approval of MOLBREEVI by March 31, 2027, in exchange for tiered royalties on U.S. net sales up to an aggregate $187.5 million, with a buy-back option tied to certain change-of-control events.
Venrock-affiliated investment entities report beneficial ownership of 20,881,288 Savara Inc. shares, representing 9.99% of the common stock as of December 31, 2025. This stake comes from common shares and pre-funded warrants held across several Venrock Healthcare Capital Partners funds.
The pre-funded warrants include a 9.99% Beneficial Ownership Blocker, which prevents additional exercises that would push the group’s ownership above that level. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Savara.
Savara Inc director Joseph S. McCracken exercised stock options on February 16, 2026 to acquire 1,807 shares of common stock at $1.76 per share. These options, granted at an exercise price of $1.76, had vested in twelve equal quarterly installments beginning on March 15, 2017. After this option exercise, McCracken directly holds 302,644 shares of Savara common stock.
Savara Inc. received an updated ownership report from TCG Crossover entities and Chen Yu. They report beneficial ownership of 12,362,205 shares of Savara common stock, representing 6.1% of the class, based on 203,467,845 shares outstanding as of November 12, 2025.
The shares are held of record by TCG Crossover Fund I, L.P., with TCG Crossover GP I, LLC as its general partner and Chen Yu as sole managing member, giving them shared voting and dispositive power. The filers state the holdings are not for the purpose of changing or influencing control of Savara.
Savara Inc. (SVRA) received an amended Schedule 13G filing from a group of Frazier Life Sciences investment entities reporting beneficial ownership of less than 5% of its common stock.
Frazier Life Sciences Public Fund, L.P. directly holds 8,343,048 shares, representing 4.1% of the class based on 203,467,845 shares outstanding as of November 12, 2025. Frazier Life Sciences X, L.P. directly holds 279,365 shares (0.1%), and Frazier Life Sciences XI, L.P. directly holds 1,239,888 shares (0.6%).
The reporting persons certify the securities were not acquired or held to change or influence control of Savara and disclaim being part of a control group, other than for limited nomination activities cited in the certification language.
Savara Inc. (SVRA) received an amended Schedule 13G from Nantahala Capital Management and its principals, Wilmot B. Harkey and Daniel Mack, reporting their beneficial ownership in the company’s common stock. As of December 31, 2025, they may be deemed to beneficially own 7,344,783 shares, representing 3.61% of Savara’s outstanding common stock.
The filing shows they have no sole voting or dispositive power, but share voting and dispositive power over all reported shares through funds and accounts managed by Nantahala. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Savara.
Savara Inc. received an updated Schedule 13G/A (Amendment No. 10) from a group of Farallon-managed investment funds reporting their beneficial ownership in the company’s common stock. The Farallon funds collectively hold 15,000,000 Common Stock Purchase Warrants, each currently exercisable to buy one Savara share.
Because the warrants contain a 9.99% Beneficial Ownership Limitation, Farallon reports beneficial ownership of 6.9% of Savara’s common stock, based on assuming all 15,000,000 warrants are exercisable within 60 days. The amendment also updates the listed individual reporting persons, adding Avner A. Husen and removing Richard B. Fried, Rajiv A. Patel, and William Seybold as of year-end 2025.
Savara Inc. entered into a First Amendment to its Loan and Security Agreement with Hercules Capital and other lenders. As amended, the agreement allows the company to borrow up to an aggregate of $105 million in term loans. The amendment resets the timing and conditions for Savara to draw up to $75 million of additional term loans, which become available only if the FDA approves its MOLBREEVI product candidate for treating aPAP. It also pushes back the initial dates for certain cash and revenue financial covenants to April 1, 2027 and September 30, 2027 if Savara’s market capitalization falls below specified thresholds, and grants lenders a first‑priority security interest in the company’s intellectual property, which can revert to a negative pledge if a related purchase agreement is terminated and unrestricted cash remains at or above $50 million.